alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 26 studies with an author at University of California, San Francisco (US) published 2013 (page 1 of 2) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 26 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults

✓ Peer-reviewed alzhub usefulness score 78 out of 100. JAMA internal medicine 2013-05-01

Participants had a mean age of 73.4 years; 62.7% were women, and 34.9% were Hispanic or nonwhite. 5 key findings →

Design: randomized controlled trial Participants: 126 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cognitive, emotional, and social benefits of regular musical activities in early dementia: randomized controlled study

✓ Peer-reviewed alzhub usefulness score 68 out of 100. The Gerontologist 2013-09-05

Purpose of the study During aging, musical activities can help maintain physical and mental health and cognitive abilities, but their rehabilitative use has not been systematically explored in persons with dementia (PWDs). 1 key finding →

Participants: 30 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Midlife risk score for the prediction of dementia four decades later

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013-09-10

A combination of modifiable vascular risk factors in midlife is highly predictive of the likelihood of dementia decades later. 1 key finding →

Design: cohort study Participants: 2,767 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA internal medicine 2013-07-01

During the 12-year follow-up period, 61 participants (7.8%) had a reported hypoglycemic event, and 148 (18.9%) developed dementia. 3 key findings →

Participants: 783 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Molecular neurodegeneration 2013-06-21

Our results suggest that the TREM2 p.R47H substitution is a risk factor for frontotemporal dementia and Parkinson's disease in addition to Alzheimer's disease. 4 key findings →

Participants: 609 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment due to Alzheimer disease in the community

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Annals of neurology 2013-08-01

The NIA-AA criteria apply to most MCI subjects in both the community and clinical trials settings; however, a sizeable proportion of subjects had conflicting biomarkers, which may be very important and need to be explored. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 58 out of 100. JAMA neurology 2013-03-01

Although there were no significant differences among the 3 groups of participants in their clinical ratings, neuropsychological test scores, hippocampal volumes (P = .60), or hippocampal glucose metabolism measurements (P = .12), there were significant group differences in their posterior cingulate glucose metabolism measurements (P = .001). 2 key findings →

Design: cross-sectional Participants: 31 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Annals of neurology 2013-03-12

Parietal and occipital lobar CMBs counts were higher in PiB(+) ADCI with moderate WMH than PiB(+) ADCI with minimal WMH, whereas PiB(-) patients with SVCI (ie, "pure" SVCI) showed both lobar and deep CMBs. 3 key findings →

Participants: 226 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neuroimaging predictors of brain amyloidosis in mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Annals of neurology 2013-08-01

As one of the first attempts to use an imaging technique that does not require amyloid-specific radioligands for identification of individuals with brain amyloidosis, our findings could lead to development of multidisciplinary/multimodality brain amyloidosis biomarkers that are reliable, minimally invasive, and widely available. 3 key findings →

Participants: 62 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Racial/ethnic differences in dementia risk among older type 2 diabetic patients: the diabetes and aging study

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Diabetes care 2013-11-22

Among type 2 diabetic patients followed for 10 years, African Americans and Native Americans had a 40-60% greater risk of dementia compared with Asians, and risk was intermediate for non-Hispanic whites and Latinos. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2013-02-11

Glial proliferation and activation are associated with disease progression in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Heightened emotional contagion in mild cognitive impairment and Alzheimer's disease is associated with temporal lobe degeneration

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2013-05-28

Emotional changes are common in mild cognitive impairment (MCI) and Alzheimer's disease (AD). 5 key findings →

Participants: 237 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

"Thinking about it for somebody else": Alzheimer's disease research and proxy decision makers' translation of ethical principles into practice

✓ Peer-reviewed alzhub usefulness score 50 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2013-02-06

Tensions exist between abstract ethical principles regarding decision-making "standards" and their translation into research decisions. 3 key findings →

Participants: 40 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed